×

Register now for access to the Parexel Biotech Content Hub

First Name
Last Name
Company Name
Job Title
Country
Thank you!
Error - something went wrong!
   

Challenging Conventional Patient Recruitment And Care Strategies For Rare Disease Studies

August 22, 2017

The number of orphan drug designations doubled between 2007 and 2014; and drugs for rare diseases accounted for 41% of new FDA-approved drugs in 2016. Aided by a variety of supportive FDA policies, orphan drugs have had a higher overall success rate than their counterparts from 2006-2015: 25% of orphan drugs advanced successfully from Phase I to FDA approval versus only 9.6% of nonorphan drugs, spurring investment from companies and giving new hope to patients suffering from heretofore untreatable diseases. Read this article to find out more. 

Previous Flipbook
Venturing into a new era of CNS drug development to improve success
Venturing into a new era of CNS drug development to improve success

Three strategies that apply multidisciplinary solutions earlier in the development process to reduce failur...

No More Flipbooks

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!